Filtered By:
Drug: Methotrexate

This page shows you your search results in order of relevance. This is page number 4.

Order by Relevance | Date

Total 117 results found since Jan 2013.

Tumor Necrosis Factor α Inhibitor Use and Decreased Risk for Incident Coronary Events in Rheumatoid Arthritis
ConclusionUse of TNFα inhibitors is associated with a decreased risk for CAD in RA; the risk decreases further with long‐term use. This should be considered when weighing the risks versus benefits of these medications.
Source: Arthritis Care and Research - February 24, 2014 Category: Rheumatology Authors: Androniki Bili, Xiaoqin Tang, Shruthi Pranesh, Rasa Bozaite, Stephanie J. Morris, Jana L. Antohe, H. Lester Kirchner, Mary Chester M. Wasko Tags: Rheumatoid Arthritis Source Type: research

Cardiovascular outcomes and systemic anti‐inflammatory drugs in patients with severe psoriasis: 5‐year follow‐up of a Danish nationwide cohort
ConclusionSystemic anti‐inflammatory treatment with methotrexate was associated with significantly lower rates of cardiovascular events during long‐term follow‐up compared to patients treated with other antipsoriatic therapies. The treatment strategy in patients with severe psoriasis may have an impact on cardiovascular outcomes and randomized trials to evaluate the cardiovascular safety and efficacy of systemic antipsoriatic therapies are called for.
Source: Journal of the European Academy of Dermatology and Venereology - October 10, 2014 Category: Dermatology Authors: O. Ahlehoff, L. Skov, G. Gislason, R. Gniadecki, L. Iversen, L.E. Bryld, S. Lasthein, J. Lindhardsen, S.L. Kristensen, C. Torp‐Pedersen, P.R. Hansen Tags: Original Article Source Type: research

Rapidly Fatal Internal Carotid Artery Mycotic Aneurysm Rupture in a Rheumatoid Patient Taking a TNF-α Inhibitor: Case Report and Literature Review
Conclusions Although fungal mycotic aneurysms of the ICA are rare, their incidence may increase with the expanded use of immunosuppressive medications. Patients with rheumatoid arthritis who take potent immunosuppression regimens may be prime candidates for mycotic aneurysms because they often have two favoring conditions: atherosclerosis and immunosuppression. These ICA aneurysms carry a high mortality rate, so early diagnosis and aggressive therapy, potentially by endovascular trapping/vessel occlusion coupled with long-term antifungal therapy, is essential.[...]Georg Thieme Verlag KG Stuttgart · New YorkArticle in Th...
Source: Journal of Neurological Surgery Part A: Central European Neurosurgery - July 21, 2014 Category: Neurosurgery Authors: Bowers, Christian A.Saad, DanyClegg, Daniel O.Ng, PerryClayton, FredericHaydoura, SouhaSchmidt, Richard H. Tags: Case Report Source Type: research

Oculopalatal tremor, facial myokymia and truncal ataxia in a patient with neurosarcoidosis
We report, to our knowledge, the first patient with neurosarcoidosis with simultaneous SPT and FM. A 49-year-old African American woman, with non-caseating granulomas in a paratracheal lymph node biopsy, presented with progressive gait disturbances for the last 3years. Neurological examination revealed ataxic speech, bilateral rotatory nystagmus, myokymia of the chin and perioral muscles, palatal tremor without ear click and marked truncal ataxia. MRI demonstrated a lesion involving the facial nucleus and the right middle cerebellar peduncle. Based on exclusion of alternative etiologies, a diagnosis of neurosarcoidosis was...
Source: Journal of Clinical Neuroscience - November 29, 2014 Category: Neuroscience Source Type: research

Drugs used to treat joint and muscle disease
Publication date: Available online 19 February 2015 Source:Anaesthesia & Intensive Care Medicine Author(s): David G. Lambert Joint disease: Arthritis can be simply broken into osteoarthritis and rheumatoid arthritis (RA). Osteoarthritis is treated with symptomatic pain relief and surgery. RA is a chronic autoimmune disease that causes inflammation of joints (leading to their destruction), tissues around joints and other organ systems. Treatment (for pain) of RA in the first instance is with non-steroidal anti-inflammatory drugs, with second-line treatment using disease-modifying antirheumatic drugs (DMARDs). DMAR...
Source: Anaesthesia and intensive care medicine - February 24, 2015 Category: Anesthesiology Source Type: research

Protective effects of methotrexate against ischemic cardiovascular disorders in patients treated for rheumatoid arthritis or psoriasis: novel therapeutic insights coming from a meta-analysis of the literature data.
CONCLUSION: Methotrexate at low doses, such those used for maintenance therapy of RA, predicted a decreased risk of CVE. Since methotrexate doesn't interfere with blood lipids, platelet aggregation or insulin resistance, the protective association may originate from mechanisms other than those exerted by antiplatelet drugs or statins. PMID: 25697810 [PubMed - as supplied by publisher]
Source: The Anatolian Journal of Cardiology - February 16, 2015 Category: Cardiology Authors: De Vecchis R, Baldi C, Palmisani L Tags: Anadolu Kardiyol Derg Source Type: research

Cardiovascular Effects of Methotrexate in Rheumatoid Arthritis Revisited.
This article overviews some mechanisms of action of methotrexate on TRF, clinical and subclinical manifestations of RA-induced atherosclerosis, and related cardiovascular morbidity and mortality. PMID: 25876749 [PubMed - as supplied by publisher]
Source: Current Medicinal Chemistry - April 15, 2015 Category: Chemistry Authors: Popkova TV, Novikova DS, Gasparyan AY, Nasonov EL Tags: Curr Med Chem Source Type: research

Inflammation modulation and cardiovascular disease prevention
Heart disease and stroke represent the major burden of health worldwide and account for a staggering 17 million deaths yearly. This pandemic is, in great part preventable through simple and modifiable preventive measures such as smoking cessation, healthy eating, regular activity and weight loss. In patients with established atherosclerotic vascular disease, lipid lowering agent have had a major impact on reducing risk, along with pharmacological treatment of elevated blood pressure and the use of anti-thrombotic medication. Despite these advances, there remains a significant residual risk and newer approaches are required...
Source: European Journal of Preventive Cardiology - May 6, 2015 Category: Cardiology Authors: Awan, Z., Genest, J. Tags: Original scientific papers Source Type: research

Closing the loop on inflammation and atherothrombosis: why perform the CIRT and CANTOS trials?
Authors: Ridker PM Abstract Inflammation contributes to all phases of the atherothrombotic process, patients with elevated inflammatory biomarkers such as high-sensitivity C-reactive protein (hsCRP) have increased cardiovascular risk, and recent work directly implicates the interleukin-1 (IL-1) and interleukin-6 (IL-6) pathways in atherogenesis. Yet, it remains unknown whether targeted inhibition of inflammation will reduce cardiovascular event rates. To address directly this fundamental hypothesis, our research group has initiated two large-scale, randomized, placebo-controlled trials using targeted anti-inflammat...
Source: Transactions of the American Clinical and Climatological Association - June 4, 2015 Category: Journals (General) Tags: Trans Am Clin Climatol Assoc Source Type: research

Clinical profile and long-term outcome of granulomatosis with polyangiitis (GPA): A corporate hospital-based study from northern India
Conclusion GPA remits with standard treatment but relapses frequently, leading to substantial morbidity. Mortality is uncommon.
Source: Indian Journal of Rheumatology - July 18, 2015 Category: Rheumatology Source Type: research

Cervical aspergillosis with dissemination to the central nervous system: Case reports and review of the literature.
CONCLUSION: IA must be considered a possibility whenever an immunocompromised patient presents with a new brain lesion. These lesions require surgical evacuation, a procedure that allows for diagnostic confirmation and enhances prognosis. Appropriate anti-fungal therapy must be started as soon as the diagnosis is confirmed. In addition, the patient's neurological exam must be repeated and images obtained periodically to monitor treatment and detect possible recurrences. PMID: 26600985 [PubMed - as supplied by publisher]
Source: Surgical Neurology International - November 25, 2015 Category: Neurosurgery Tags: Surg Neurol Int Source Type: research

Differential diagnosis of stroke: Subacute leukencephalopathy following high-dose methotrexate therapy in a young patient with osteosarcoma
Publication date: Available online 10 November 2015 Source:Interdisciplinary Neurosurgery Author(s): Viktoriya Brajnik, Oliver Kastrup
Source: Interdisciplinary Neurosurgery - January 21, 2016 Category: Neurosurgery Source Type: research

Dextromethorphan: An update on its utility for neurological and neuropsychiatric disorders
Publication date: Available online 28 January 2016 Source:Pharmacology & Therapeutics Author(s): Linda Nguyen, Kelan L. Thomas, Brandon P. Lucke-Wold, John Z. Cavendish, Molly S. Crowe, Rae R. Matsumoto Dextromethorphan (DM) is a commonly used antitussive and is currently the only FDA-approved pharmaceutical treatment for pseudobulbar affect. Its safety profile and diverse pharmacologic actions in the central nervous system have stimulated new interest for repurposing it. Numerous preclinical investigations and many open-label or blinded clinical studies have demonstrated its beneficial effects across a var...
Source: Pharmacology and Therapeutics - January 28, 2016 Category: Drugs & Pharmacology Source Type: research

Jane Cooke Wright (1919-2013): Pioneering oncologist, woman and humanitarian
Jane Wright was a fundamental researcher in cancer chemotherapy in the 1950s–1980s and was one of the first scientists to test anti-cancer drugs on humans rather than solely on mice, discovering the use of the popular antimetabolite drug methotrexate on solid tumours. From her research she was able to conclude which specific anti-cancer agents would have the greatest lethal effect on a patient’s certain cancer type and she invented a method of delivering chemotherapy agents directly to an internal cancer site. During a time when the Civil Rights in the United States of America were undergoing a transformation t...
Source: Journal of Medical Biography - February 12, 2016 Category: History of Medicine Authors: Crosby, H. L. Tags: Original Articles Source Type: research

Neurological Involvement in the Course of Scleromyxedema: A Case Report
Scleromyxedema is a rare disease of unknown etiology primarily affecting the skin, characterized by generalized papular eruption, dermal fibroblast proliferation with mucin deposition, and a monoclonal gammopathy. Neurological impairment is a rare but sometimes fatal complication of scleromyxedema that should be rapidly identified to prevent significant morbidity and mortality. A 63-year-old Caucasian man had a 2-year history of scleromyxedema, and was under immunosuppressive treatment with ciclosporine and methotrexate.
Source: Journal of Stroke and Cerebrovascular Diseases - June 5, 2016 Category: Neurology Authors: Francesca Spagnolo, Cecilia Nozzoli, Augusto Rini, Salvatore La Spada, Vincenzo De Marco, Bruno Passarella Tags: Case Studies Source Type: research